全文获取类型
收费全文 | 3208593篇 |
免费 | 229462篇 |
国内免费 | 8652篇 |
专业分类
耳鼻咽喉 | 43198篇 |
儿科学 | 107175篇 |
妇产科学 | 88601篇 |
基础医学 | 453507篇 |
口腔科学 | 89168篇 |
临床医学 | 293137篇 |
内科学 | 627412篇 |
皮肤病学 | 75541篇 |
神经病学 | 262011篇 |
特种医学 | 123248篇 |
外国民族医学 | 1009篇 |
外科学 | 477900篇 |
综合类 | 67434篇 |
现状与发展 | 5篇 |
一般理论 | 1264篇 |
预防医学 | 248289篇 |
眼科学 | 72218篇 |
药学 | 233950篇 |
11篇 | |
中国医学 | 6561篇 |
肿瘤学 | 175068篇 |
出版年
2019年 | 24984篇 |
2018年 | 35404篇 |
2017年 | 27222篇 |
2016年 | 31318篇 |
2015年 | 35293篇 |
2014年 | 48562篇 |
2013年 | 73681篇 |
2012年 | 97594篇 |
2011年 | 103353篇 |
2010年 | 62179篇 |
2009年 | 59355篇 |
2008年 | 96656篇 |
2007年 | 102514篇 |
2006年 | 104482篇 |
2005年 | 100100篇 |
2004年 | 96826篇 |
2003年 | 93501篇 |
2002年 | 90151篇 |
2001年 | 152890篇 |
2000年 | 156676篇 |
1999年 | 132172篇 |
1998年 | 37996篇 |
1997年 | 33883篇 |
1996年 | 33958篇 |
1995年 | 32903篇 |
1994年 | 30319篇 |
1993年 | 28261篇 |
1992年 | 103563篇 |
1991年 | 100046篇 |
1990年 | 97268篇 |
1989年 | 93929篇 |
1988年 | 85868篇 |
1987年 | 84669篇 |
1986年 | 79284篇 |
1985年 | 75939篇 |
1984年 | 56624篇 |
1983年 | 47987篇 |
1982年 | 28544篇 |
1981年 | 25573篇 |
1979年 | 50461篇 |
1978年 | 35871篇 |
1977年 | 30405篇 |
1976年 | 28348篇 |
1975年 | 30074篇 |
1974年 | 35813篇 |
1973年 | 34129篇 |
1972年 | 31771篇 |
1971年 | 29579篇 |
1970年 | 27256篇 |
1969年 | 25993篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
22.
23.
24.
25.
26.
Daniel J. Snyder Thomas R. Kroshus Aakash Keswani Evan B. Garden Karl M. Koenig Kevin J. Bozic David S. Jevsevar Jashvant Poeran Calin S. Moucha 《The Journal of arthroplasty》2019,34(4):613-618
Background
Nursing Home Compare (NHC) ratings, created and maintained by Medicare, are used by both hospitals and consumers to aid in the skilled nursing facility (SNF) selection process. To date, no studies have linked NHC ratings to actual episode-based outcomes. The purpose of this study was to evaluate whether NHC ratings are valid predictors of 90-day complications, readmission, and bundle costs for patients discharged to an SNF after primary total joint arthroplasty (TJA).Methods
All SNF-discharged primary TJA cases in 2017 at a multihospital academic health system were queried. Demographic, psychosocial, and clinical variables were manually extracted from the health record. Medicare NHC ratings were then collected for each SNF. For patients in the Medicare bundle, postacute and total bundle cost was extracted from claims.Results
Four hundred eighty-eight patients were discharged to a total of 105 unique SNFs. In multivariate analysis, overall NHC rating was not predictive of 90-day readmission/major complications, >75th percentile postacute cost, or 90-day bundle cost exceeding the target price. SNF health inspection and quality measure ratings were also not predictive of 90-day readmission/major complications or bundle performance. A higher SNF staffing rating was independently associated with a decreased odds for >75th percentile 90-day postacute spend (odds ratio, 0.58; P = .01) and a 90-day bundle cost exceeding the target price (odds ratio = 0.69; P = .02) but was similarly not predictive of 90-day readmission/complications.Conclusion
Results of our study suggest that Medicare's NHC tool is not a useful predictor of 90-day costs, complications, or readmissions for SNFs within our health system. 相似文献27.
28.
29.
N. V. Bashmakova G. N. Chistiakova I. A. Gazieva Y. M. Trapeznikova D. O. Mazurov 《Gynecological endocrinology》2015,31(10):31-33
AbstractThis study was undertaken to compare the concentrations of pro- and anti-angiogenic growth factors, nitric oxide (NO) stable metabolites in maternal serum and embryonic left ventricular (LV) isovolumic relaxation time (IRT, ms) during the first trimester in two groups of women: with pregnancy conceived by assisted reproductive technologies (ART, n?=?39) and normally conceived (control group, n?=?68) pregnancy. The concentration of vasoconstrictor endothelin 1 was 45.5 times more in ART than in control group. On the contrary, the concentrations of NO stable metabolites in ART were 1.9 times less than in control women. The assessment of angiogenic suppressors in ART women demonstrates the decrease in s-endoglin concentration was 1.6 times and in soluble receptor to vascular endothelial growth factor concentration was 2.0 times in comparison with control group. There was a significant increase in LV IRT in ART embryos in comparison to control ones. These data suggest significant changes in pro- anti-angiogenic factors balance and increase in vascular impedance in ART-conceived embryos. 相似文献
30.
Arjenne H.M. Gussenhoven Amika S. Singh S. Theo Goverts Marten van Til Johannes R. Anema Sophia E. Kramer 《International journal of audiology》2015,54(8):507-517
Objective: A multidisciplinary vocational rehabilitation programme, the Vocational Enablement Protocol (VEP) was developed to address the specific needs of employees with hearing difficulties. In the current study we evaluated the process of implementing the VEP in audiologic care among employees with hearing impairment. Design: In conjunction with a randomized controlled trial, we collected and analysed data on seven process parameters: recruitment, reach, fidelity, dose delivered, dose received and implemented, satisfaction, and perceived benefit. Study sample: Sixty-six employees with hearing impairment participated in the VEP. The multidisciplinary team providing the VEP comprised six professionals. Results: The professionals performed the VEP according to the protocol. Of the recommendations delivered by the professionals, 31% were perceived as implemented by the employees. Compliance rate was highest for hearing-aid uptake (51%). Both employees and professionals were highly satisfied with the VEP. Participants rated good perceived benefit from it. Conclusions: Our results indicate that the VEP could be a useful treatment for employees with hearing difficulties from a process evaluation perspective. Implementation research in the audiological setting should be encouraged in order to further provide insight into parameters facilitating or hindering successful implementation of an intervention and to improve its quality and efficacy. 相似文献